Disposition kinetics of human epidermal growth factor (hEGF1-53) and its truncated fragment (hEGF1-48) in rats.
Clearance of human epidermal growth factor (hEGF1-53) has been proposed to be mediated by a receptor pathway involving a typical cascade of ligand-receptor endocytosis and lysosomal degradation. Deletion of the C-terminal pentapeptide from hEGF1-53, which yields hEGF1-48, is known to be associated with a marked reduction in receptor binding. We defined the intravenous (iv)-bolus (acute exposure) and the iv-infusion (prolonged exposure) pharmacokinetics of hEGF1-53 and hEGF1-48 in rats to investigate the impact of the deletion of C-terminal pentapeptide on the EGF clearance using a validated, sensitive ELISA method for quantitation of the peptides in plasma. Both peptides at the low iv bolus dose of 10 micrograms/kg were cleared from plasma with unusually high clearances (CLtot: 128 +/- 31 ml/min/kg for hEGF1-53 and 168 +/- 47 ml/min/kg for hEGF1-48), which are virtually complete within 4-min postdose, and the difference in the overall pharmacokinetics is of minor significance. A 10-fold increase in bolus dose to 100 micrograms/kg decreased clearances 3- to 6-fold, indicating a nonlinear kinetics for both peptides; however, hEGF1-48 was cleared (52 +/- 11 ml/min/kg) 2.5-fold faster than hEGF1-53. A similar nonlinear kinetics was also noticed for both peptides when they were administered by a 2-hr iv infusion at 30 and 300 micrograms/kg doses. hEGF1-48 at the low and high infusion doses was cleared at 126 +/- 16 and 33.7 +/- 14.5 ml/min/kg, respectively, which are 4-fold greater than the corresponding clearance rates of hEGF1-53. These observations suggest that a) deletion of C-terminal pentapeptide is associated with a faster clearance of the growth factor and b) the receptor clearance pathway may be more sensitive to saturation with hEGF1-53 than with hEGF1-48 at low microgram dose levels. hEGF1-53 at the low infusion dose of 30 micrograms/kg was cleared (32.1 +/- 6.2 ml/min/kg) 4-fold slower in comparison with the low bolus dose of 10 micrograms/kg, indicating a remarkable injection mode-dependent disposition kinetics for hEGF1-53, which does not exist for hEGF1-48. The overall results suggest that deletion of C-terminal pentapeptide leads to faster clearance of the growth factor, and the degree of the impact of deletion of C-terminal pentapeptide on the global pharmacokinetics is also dependent on the length of exposure of the receptor to the ligand. The negative relationship between receptor binding and plasma clearance for the two peptides remains to be elucidated at the molecular and receptor levels.
Kuo
B S
BS
Department of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Ann Arbor, MI 48105, USA.
Nordblom
G D
GD
Dudeck
R C
RC
Kirkish
L S
LS
Wright
D S
DS
D000595:Amino Acid Sequence; D000818:Animals; D004815:Epidermal Growth Factor / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
D010446:Peptide Fragments; C102344:epidermal growth factor (1-48); C102345:epidermal growth factor (1-53); D004815:Epidermal Growth Factor; D066246:ErbB Receptors